Does Canada Have an Agreement with Pfizer
This press release contains forward-looking information about Pfizer`s efforts to combat COVID-19, the collaboration between BioNTech and Pfizer in the development of a potential COVID-19 vaccine, an agreement with the Government of Canada for the supply of BNT162 and other potential agreements, the BNT162 NRMO vaccine program and modRNA candidates BNT162b2 and BNT162b1 (including qualitative assessments of available data, potential benefits, such as clinical trial expectations and the timing of submission of regulatory filings, planned manufacturing, delivery and distribution), which involve significant risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statements. APAs have the obligations of a contract, but are structured to allow flexibility in the face of uncertainties in the development of new vaccines. Essentially, they allow the purchase of something that does not yet exist. As the government prepares for the future, the country is still grappling with a turbulent third wave, with the only cure being more vaccines in more weapons. Canada continues to work closely with suppliers to ensure we have enough cans to meet not only our current needs, but also those of tomorrow. “This agreement is part of our commitment to fight the pandemic by supporting the global supply of our vaccine candidate. Our teams are working diligently to ensure that the lead product candidate undergoes clinical development in order to request a regulatory review as early as October. At the same time, Pfizer and BioNTech continue to expand their production capacity to produce up to 100 million doses in 2020 and more than one billion doses in 2021. Since we launched the Lightspeed project, our goal has always been clear: to make a potential vaccine available to the public as quickly as possible – worldwide.
This agreement is another step in that direction,” said Sean Marett, Chief Commercial Officer and Chief Commercial Officer at BioNTech. Based on expert advice, Canada has implemented a comprehensive vaccine strategy to provide all Canadians with the most promising COVID-19 vaccines. At the time, it was unclear which vaccines would be successful and when. The agreement with Merck provides Canada with 500,000 oral antiviral treatments for COVID-19, molnupiravir, with options of up to 500,000 more, subject to Health Canada approval. But less than a month after the contract was signed, Health Canada`s senior medical advisor, Dr. Supriya Sharma, reported that her department was about two weeks away from giving the green light to the vaccine. He said the country of 38 million people also has options for tens of millions more in the coming years if they are needed. He added that the government is also discussing with other vaccine manufacturers its plans for booster injections. “We remain committed to working with the Government of Canada to combat this pandemic and are pleased with their collaborative approach to addressing a national COVID-19 vaccination strategy with public health officials,” said Cole C.
Pinnow, President of Pfizer Canada. “Through our joint efforts, we know that there is no health problem that we cannot address. In addition to their commitments with governments, Pfizer and BioNTech have expressed interest in potential delivery to the COVAX facility, a mechanism established by Gavi, the Vaccine Alliance, the Coalition for Epidemic Preparedness Innovations (CEPI) and the World Health Organization (WHO) to provide governments, including those in emerging markets, with Rapid access to a broad portfolio of COVID-19 vaccine candidates using a range of technology platforms. produced by several manufacturers around the world. The Canadian government has contracted for supplies needed to administer nearly 75 million doses of COVID-19 vaccines, including syringes, needles and gauze. To date, we have received all deliveries. The agreement with Pfizer provides Canada with an initial $1 million in oral antiviral treatments for COVID-19, subject to Health Canada`s approval. Pfizer filed an ongoing application for approval with Health Canada earlier this week.
Prime Minister Justin Trudeau said Friday that Canada has reached an agreement with Pfizer on 35 million recalls next year and 30 million in 2023 if the effectiveness of COVID-19 vaccines decreases over time and needs to be strengthened. In addition to providing booster doses, the agreements provide flexibility in purchasing new second-generation COVID-19 vaccine adaptations, by . B to protect against mutations or variants of concern, and vaccines designed for younger populations. Prime Minister Justin Trudeau said Canada has reached an agreement with Pfizer on 35 million COVID-19 booster doses for next year and 30 million in 2023 with options for tens of millions more in the coming years, and that Canada will have nearly 50 million excess doses of the four vaccines it has approved, and perhaps 124 million more from Sanofi. Medicago and Novavax if they successfully complete their Phase 3 clinical trials. Under the agreement, Pfizer will supply 35 million doses in 2022 with options to purchase up to 30 million additional doses. In 2023, Pfizer will provide 30 million doses as part of the deal with options to purchase up to 30 million additional doses. The agreement also provides for the possible purchase of cans in 2024. The terms of the agreement also include potentially adapted versions of the vaccine. In February 2021, an additional contract with Verity Pharmaceuticals Canada Inc./Serum Institute of India was announced. On July 27, Pfizer and BioNTech announced that following a comprehensive review of preclinical and clinical data from Phase 1/2 clinical trials and in consultation with the FDA`s Center for Biologics Evaluation and Research (CBER) and other global regulatory agencies, the companies selected the BNT162b2 vaccine candidate to enter a Phase 2/3 trial.
.
最新記事 by kabumori@yamanouchi (全て見る)
- 5.8 Agreement of Subject and Verb Latin - 2022年6月8日
- Y(Uk)3 the Contracts (Rights of Third Parties) Act 1999 - 2022年4月21日
- Work Agreement Duration - 2022年4月20日
